AnaptysBio (ANAB) said Friday that its board has approved the buyback of up to $100 million common shares, effective through March 31, 2026.
The new buyback program is in addition to the company's remaining $6.4 million repurchase capacity under the previous $75 million share buyback program, AnaptysBio said.